These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 172562)

  • 1. Humoral and cellular immune responses to an envelope-associated antigen of herpes simplex virus.
    Zaia JA; Palmer EL; Feorino PM
    J Infect Dis; 1975 Dec; 132(6):660-6. PubMed ID: 172562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenic properties of formalin herpes antigen prepared from cell cultures.
    Benda R; Dbalý V
    J Hyg Epidemiol Microbiol Immunol; 1973; 17(2):237-49. PubMed ID: 4354219
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of the humoral and cellular immune response after immunization with live, UV inactivated herpes simplex virus and a subunit vaccine and efficacy of these immunizations.
    Cappel R
    Arch Virol; 1976; 52(1-2):29-35. PubMed ID: 187150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stimulation of peripheral blood lymphocytes by herpes simplex virus in vitro.
    Scriba M
    Infect Immun; 1974 Sep; 10(3):430-6. PubMed ID: 4372170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of expression of herpes simplex virus (HSV) glycoprotein D in vaccinia recombinants affects their ability to protect from cutaneous HSV-2 disease.
    Wachsman M; Aurelian L; Smith CC; Perkus ME; Paoletti E
    J Infect Dis; 1989 Apr; 159(4):625-34. PubMed ID: 2538519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus.
    Meignier B; Jourdier TM; Norrild B; Pereira L; Roizman B
    J Infect Dis; 1987 May; 155(5):921-30. PubMed ID: 3031174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune responses to herpes simplex virus in guinea pigs (footpad model) and mice immunized with vaccinia virus recombinants containing herpes simplex virus glycoprotein D.
    Aurelian L; Smith CC; Wachsman M; Paoletti E
    Rev Infect Dis; 1991; 13 Suppl 11():S924-34. PubMed ID: 1664130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines.
    Weinberg A; Merigan TC
    J Immunol; 1988 Jan; 140(1):294-9. PubMed ID: 2826591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a nucleic acid free herpetic subunit vaccine.
    Cappel R; de Cuyper F; Rickaert F
    Arch Virol; 1980; 65(1):15-23. PubMed ID: 6252864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of cellular immunity to herpes simplex virus: relationship to the humoral immune response.
    Rosenberg GL; Notkins AL
    J Immunol; 1974 Mar; 112(3):1019-25. PubMed ID: 4359780
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunogenicity of subviral herpes simplex virus preparations: protection of mice against intraperitoneal infection with live virus.
    Kutinová L; Vonka V; Slichtová V
    Acta Virol; 1980 Dec; 24(6):391-8. PubMed ID: 6111199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity of subviral herpes simplex virus preparations. I. Formation of neutralizing antibodies in different animal species after administration of herpes simplex virus solubilized antigens.
    Kutinová L; Slichtová V; Vonka V
    Arch Virol; 1979; 61(1-2):141-7. PubMed ID: 229789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal models.
    Mishkin EM; Fahey JR; Kino Y; Klein RJ; Abramovitz AS; Mento SJ
    Vaccine; 1991 Mar; 9(3):147-53. PubMed ID: 1645898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonvirion antigens produced by herpes simplex viruses 1 and 2.
    Tarro G; Sabin AB
    Proc Natl Acad Sci U S A; 1973 Apr; 70(4):1032-6. PubMed ID: 4352219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine.
    Straus SE; Savarese B; Tigges M; Freifeld AG; Krause PR; Margolis DM; Meier JL; Paar DP; Adair SF; Dina D
    J Infect Dis; 1993 May; 167(5):1045-52. PubMed ID: 8387560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yeast-derived glycoprotein B-1 of herpes simplex virus (HSV) as a candidate for an HSV vaccine.
    Kino Y
    Adv Exp Med Biol; 1990; 278():183-90. PubMed ID: 1963033
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro stimulation of sensitized lymphocytes by herpes simplex virus and vaccinia virus.
    Rosenberg GL; Farber PA; Notkins AL
    Proc Natl Acad Sci U S A; 1972 Mar; 69(3):756-60. PubMed ID: 4335071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection from oral herpes simplex virus infection by a nucleic acid-free virus vaccine.
    Kitces EN; Morahan PS; Tew JG; Murray BK
    Infect Immun; 1977 Jun; 16(3):955-60. PubMed ID: 197013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a virion envelope herpes simplex virus vaccine against experimental skin infections in hairless mice.
    Klein RJ; Buimovici-Klein E; Moser H; Moucha R; Hilfenhaus J
    Arch Virol; 1981; 68(2):73-80. PubMed ID: 6264897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.